Cargando…

Adjuvant Radioiodine for Intermediate-Risk Papillary Thyroid Cancer—To Treat or Not to Treat

Detalles Bibliográficos
Autores principales:	van Velsen, Evert F S, Verburg, Frederik A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505540/ https://www.ncbi.nlm.nih.gov/pubmed/36964916 http://dx.doi.org/10.1210/clinem/dgad171

Ejemplares similares

Using nomograms to predict the presence of papillary thyroid carcinoma
por: van Velsen, Evert F. S., et al.
Publicado: (2023)

To Treat or Not to Treat: The Role of Adjuvant Radioiodine Therapy in Thyroid Cancer Patients
por: Carballo, Marilee, et al.
Publicado: (2012)

Is papillary thyroid microcarcinoma an indolent tumor?: A retrospective study on 280 cases treated with radioiodine
por: Gao, Xuemei, et al.
Publicado: (2016)

Second Adjuvant Radioiodine Therapy after Reoperation for Locoregionally Persistent or Recurrent Papillary Thyroid Carcinoma
por: Cadena-Piñeros, Enrique, et al.
Publicado: (2022)

Delayed Initial Radioiodine Adjuvant Therapy Does Affect Biochemical Response in Intermediate- to High-Risk Differentiated Thyroid Cancer
por: Yu, Feng, et al.
Publicado: (2021)

Pediatric papillary thyroid cancer: current management challenges
por: Verburg, Frederik A, et al.
Publicado: (2016)

Faecalibacterium prausnitzii in Differentiated Thyroid Cancer Patients Treated with Radioiodine
por: Fernandes, Ana, et al.
Publicado: (2023)

The EANM guideline on radioiodine therapy of benign thyroid disease
por: Campennì, Alfredo, et al.
Publicado: (2023)

Efficacy of anlotinib combined with radioiodine to treat scalp metastasis of papillary thyroid cancer: A case report and review of literature
por: Zhang, Li-Yong, et al.
Publicado: (2023)

Evaluating Disease-specific Survival Prediction of Risk Stratification and TNM Systems in Differentiated Thyroid Cancer
por: van Velsen, Evert F S, et al.
Publicado: (2022)

Clinical Outcomes of N1b Papillary Thyroid Cancer Patients Treated with Two Different Doses of Radioiodine Ablation Therapy
por: Jin, Meihua, et al.
Publicado: (2020)

Radioiodine adjuvant therapy in differentiated thyroid cancer: An update and reconsideration
por: Sun, Yu-qing, et al.
Publicado: (2022)

Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project
por: Taprogge, Jan, et al.
Publicado: (2023)

GADD45B Transcript Is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated With Total Thyroidectomy and Radioiodine Therapy
por: Barros-Filho, Mateus C., et al.
Publicado: (2020)

Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to Treat Patients with Radioiodine-Refractory Differentiated Thyroid Carcinoma: Expert Perspectives
por: Verburg, Frederik A., et al.
Publicado: (2021)

Is radioiodine administration in patients with papillary thyroid multifocal microcarcinoma unnecessary?
por: Krčálová, Eva, et al.
Publicado: (2016)

Papillary Thyroid Cancer in Struma Testis with Malignant Transformation in the Lung Associated with Trisomy 17 Successfully Treated with Total Thyroidectomy and Radioiodine Ablation
por: Barakat, Shadi, et al.
Publicado: (2014)

Initial Evaluation of Therapy Response after Adjuvant Radioiodine Therapy in Patients with Early-Stage Papillary Thyroid Cancer—Does Time Matter?
por: Grawe, Freba, et al.
Publicado: (2022)

The role of Hashimoto thyroiditis in predicting radioiodine ablation efficacy and prognosis of low to intermediate risk differentiated thyroid cancer
por: Albano, Domenico, et al.
Publicado: (2021)

Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer
por: Gao, Haiyan, et al.
Publicado: (2023)

Ablation therapy using a low dose of radioiodine may be sufficient in low- to intermediate-risk patients with follicular variant papillary thyroid carcinoma
por: Li, Fuxin, et al.
Publicado: (2020)

Added Value of Postoperative Radioiodine Scan for Staging and Risk Stratification in Papillary Thyroid Microcarcinoma
por: Kaewchur, Tawika, et al.
Publicado: (2021)

High RPMB predicts poor disease-free survival of male N1 papillary thyroid cancer after adjuvant radioiodine therapy
por: An, Ning, et al.
Publicado: (2022)

Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer
por: Ha, Seunggyun, et al.
Publicado: (2015)

Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer
por: Huillard, Olivier, et al.
Publicado: (2017)

The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer
por: Colombo, Carla, et al.
Publicado: (2020)

Development of prognostic signatures for intermediate-risk papillary thyroid cancer
por: Brennan, Kevin, et al.
Publicado: (2016)

Radioactive iodine in low- to intermediate-risk papillary thyroid cancer
por: Zhao, Hengqiang, et al.
Publicado: (2022)

The BRAF(V600E) mutation in papillary thyroid microcarcinoma with intermediate-risk to high-risk features: does the mutation have an effect on clinical response to radioiodine therapy?
por: Shen, Guohua, et al.
Publicado: (2019)

Perioperative diagnostics of patients referred for radioiodine therapy of differentiated thyroid carcinoma: referral center experience in an iodine-insufficient country
por: Eilsberger, Friederike, et al.
Publicado: (2020)

Synergic radiosensitization of sinomenine hydrochloride and radioiodine on human papillary thyroid carcinoma cells
por: Zhao, Aomei, et al.
Publicado: (2021)

Occurrence of symptomatic meningioma as a second neoplasm in patients with differentiated thyroid cancer treated with radioiodine
por: Damle, Nishikant Avinash, et al.
Publicado: (2012)

The Relationship between Oxidative Status and Radioiodine Treatment Qualification among Papillary Thyroid Cancer Patients
por: Buczyńska, Angelika, et al.
Publicado: (2023)

Blood Profiles in the Prediction of Radioiodine Refractory Papillary Thyroid Cancer: A Case–Control Study
por: Liu, Hanqing, et al.
Publicado: (2023)

Acute Myeloid Leukemia after Low-Dose Radioiodine Therapy for Papillary Thyroid Carcinoma
por: Alsaud, Arwa, et al.
Publicado: (2020)

Risk of needing completion thyroidectomy for low‐risk papillary thyroid cancers treated by lobectomy
por: DiMarco, A. N., et al.
Publicado: (2019)

Correlation of thyroid hormone measurements with thyroid stimulating hormone stimulation test results in radioiodine‐treated cats
por: Wakeling, Jennifer, et al.
Publicado: (2020)

Identification of Circulating Exosomal microRNAs Associated with Radioiodine Refractory in Papillary Thyroid Carcinoma
por: Li, Genpeng, et al.
Publicado: (2022)

Efficacy of Low-Dose Radioiodine Ablation in Low- and Intermediate-Risk Differentiated Thyroid Cancer: A Retrospective Comparative Analysis
por: Gómez-Pérez, Ana María, et al.
Publicado: (2020)

Therapeutic response and long-term outcome of differentiated thyroid cancer with pulmonary metastases treated by radioiodine therapy
por: Yang, Jing, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c52q46o864i8o9sk43nc71d5a7